Craft
  • Home
  •  / Edwards Lifesciences
Edwards Lifesciences

Edwards Lifesciences

Countries

100

FY, 2020

Revenue

$5.2 B

FY, 2021

Market Capitalization

$54.4 B

2022-09-20

Edwards Lifesciences Summary

Company summary

Overview
Edwards Lifesciences is a company operating as a global provider of patient-focused medical solutions for structural heart disease and critical care monitoring. The company develops heart valve therapies and manufactures heart valve systems and repair products used to replace or repair diseased or defective heart valves. It also offers hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.
Type
Public
Founded
1958
HQ
Irvine, CA, US | view all locations
Website
http://www.edwards.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Donald E. Bobo

    Donald E. Bobo, Corporate Vice President, Strategy & Corporate Development

  • Michael A. Mussallem

    Michael A. Mussallem, Chairman and Chief Executive Officer

    • Todd J. Brinton

      Todd J. Brinton, Corporate Vice President, Advanced Technology, Chief Scientific Officer

    • Daveen Chopra

      Daveen Chopra, Corporate Vice President, Surgical Structural Heart

    Operating MetricsView all

    Patents and Patent Applications

    4.7K
    20.5%

    FY, 2019

    Manufacturing Facilities

    7

    FY, 2020

    Countries

    100

    FY, 2020

    LocationsView all

    41 locations detected

    • Irvine, CA HQ

      United States

      1 Edwards Way

    • Draper, UT

      United States

      12050 Lone Peak Pkwy

    • Washington, DC

      United States

      601 13th St NW #350

    • Macquarie Park, NSW

      Australia

      40 Talavera Rd

    • Wien, Wien

      Austria

      Vorgartenstraße 206C

    • Dilbeek, Vlaanderen

      Belgium

      Pontbeekstraat 4

    and 35 others

    Edwards Lifesciences Financials

    Summary financials

    Revenue (Q2, 2022)
    $1.4B
    Gross profit (Q2, 2022)
    $1.1B
    Net income (Q2, 2022)
    $406.4M
    Cash (Q2, 2022)
    $1.2B
    EBIT (Q2, 2022)
    $459.5M
    Enterprise value
    $53.3B

    Footer menu